We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MicroRNA Regulation Critical for Development of Pediatric Brain Tumors

By Gerald M. Slutzky, PhD
Posted on 14 Dec 2016
Cancer researchers have uncovered the critical role played by microRNA regulation in the development of childhood brain tumors.

MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. More...
Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

Low-grade gliomas and glioneuronal tumors represent the most frequent primary tumors of the central nervous system in children. Unlike many other types of cancerous tumors, these low-grade pediatric gliomas appear to have few genetic mutations, so the molecular basis for their development has been unclear.

Investigators at Johns Hopkins University (Baltimore, MD, USA) chose to examine a possible role for miRNAs in the development of pediatric gliomas, since miRNAs had been identified as molecular regulators of protein expression/translation that could repress multiple mRNAs concurrently through base pairing, and had an important role in other cancers.

The investigators used the NanoString (Seattle, WA, USA) digital counting system to analyze the expression levels of 800 microRNAs in nine low-grade glial and glioneuronal tumor types.

They reported in the October 14, 2016, online edition of the journal Modern Pathology that a set of 61 microRNAs were differentially expressed in tumors compared with normal brain tissues, and several showed levels varying by tumor type. MicroRNAs miR-4488 and miR-1246 were overexpressed in dysembryoplastic neuroepithelial tumors compared with brain tissue and other tumors, while miR-487b was variably under-expressed in pediatric glioma lines compared with human neural stem cells.

The investigators employed lentiviral vectors to overexpress miR-487b in a pediatric glioma cell line. These modified cells were found to be less cancer-like, forming 30% fewer colonies and had decreased levels of some proteins, such as Nestin (neuroectodermal stem cell marker). Nestin is known to be important in both early development and in cancers.

Senior author Dr. Fausto J.Rodriguez, associate professor of pathology at Johns Hopkins University, said, "Physicians might be able to look at the levels of this and other microRNAs in blood or cerebrospinal fluid to test for the presence of cancer. Researchers might also be able to target microRNAs directly, altering their levels to make cancer cells less likely to form tumors. By gaining a better understanding of the fine genetic differences between cancers and healthy tissues, we can develop better therapeutic or prognostic strategies."

Related Links:
Johns Hopkins University
NanoString

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.